Jasper Therapeutics Inc

Jasper Therapeutics has secured approximately $132 million in gross proceeds through a private placement of non-voting convertible preferred stock led by Affinity Asset Advisors and Ikarian Capital, following the completion of its all-stock acquisition of Kira Pharmaceuticals on July 16, 2026. The financing is expected to fund planned operations through the second half of 2028. The combined company reported second quarter 2026 financial results, with cash and cash equivalents of $7.3 million as of June 30, 2026, research and development expenses of $5.1 million, general and administrative expenses of $4.1 million, and a net loss of $2.8 million, or $0.10 per share, compared with a net loss of $0.03 million, or $1.74 per share, in the year-ago quarter. Jasper is advancing a portfolio of clinical-stage therapies including KP-104, briquilimab, and KP-701, with interim Phase 2 data for KP-104 in rare renal indications expected in the fourth quarter of 2026, an End-of-Phase 2 meeting with the FDA for KP-104 in PNH planned for the first half of 2027, a pre-BLA meeting for briquilimab expected in the first quarter of 2027, and a CTA or IND filing for KP-701 planned for the first quarter of 2027.

Jasper Therapeutics has completed its all-stock acquisition of Kira Pharmaceuticals and concurrently raised approximately $132 million in a private placement co-led by Affinity Asset Advisors and Ikarian Capital. The combined company will advance a pipeline of biologic agents for immunologically-driven disorders, including KP-104 for paroxysmal nocturnal hemoglobinuria and renal indications, briquilimab for severe combined immunodeficiency, and KP-701 for autoantibody-mediated diseases. Kira also out-licensed two assets, KP-301 and KP-402, to Mirador Therapeutics for a $12 million upfront payment plus potential milestone payments. The combined financing and transactions are expected to fund operations through the second half of 2028, covering multiple clinical milestones such as KP-104 Phase 2 results and a pre-Biologics License Application meeting for briquilimab. The combined company will continue trading on Nasdaq under the ticker symbol JSPR.

The chronic spontaneous urticaria market across the seven major markets reached approximately 2 billion dollars in 2025, with the United States holding the largest share. Total diagnosed prevalent cases of chronic urticaria in those markets were about 4.8 million in 2025 and are expected to rise by 2036. Key companies advancing new therapies include Celldex Therapeutics, Sanofi, Jasper Therapeutics, Evommune, Blueprint Medicines, ARS Pharmaceuticals, Nurix Therapeutics, InflaRx, and Otsuka Holdings through Taiho Pharmaceutical. Promising pipeline candidates such as barzolvolimab, rilzabrutinib, briquilimab, EVO756, BLU-808, ARS-1, bexobrutideg, INF904, and TAS5315 are in clinical development, while recent approvals of DUPIXENT and RHAPSIDO have already broadened treatment options beyond traditional anti-IgE biologics.